Shire plc has joined Agios Pharmaceuticals in announcing the appointment of Ian Clark to the Board of Directors.
Mr. Clark served as Chief Executive Officer and Director of Genentech Inc (part of the Roche Group) and Head of North American Commercial Operations for Roche until December 31, 2016, having held several senior strategy, operations and commercially focused roles since joining Genentech in 2003. Prior to this Mr. Clark held various senior operational, sales and marketing roles in other pharmaceutical and healthcare companies. He is currently appointed as a Non-Executive Director of TerraVia Holdings Inc. where he serves as Chairman of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee.
Susan Kilsby, Shire’s Chairman, commented: “We are very pleased to announce Ian’s appointment at this important time; his in-depth knowledge of the biotechnology sector and breadth of operational experience stand to serve Shire well as we look forward to growing our business and addressing unmet patient needs world-wide.”
Mr. Clark added: “Shire has demonstrated commitment to being the global leader in rare diseases and to delivering value to its patients, physicians, shareholders and other stakeholders. I look forward to working with Susan and the rest of the Board in pursuing a successful future for the Company.”
Do you work in the Massachusetts Life Sciences sector? – Take the Human Capital Pipeline Survey https://www.liftstream.com/pipelinesurvey.html